Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness

Thrombosis Research

Volumn 121, Issue 4, 2008, Pages 463-468

  Fontana, Pierre ^a   Senouf, David ^a   Mach, François ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Clopidogrel; Dose; Platelets; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PHOSPHOPROTEIN; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

ADULT; AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OUTPATIENTS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 38649131003     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.06.012     Document Type: Article

References (30)

1. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409 (2001) 202-207
2. Gurbel P.A., and Bliden K.P. Durability of platelet inhibition by clopidogrel. Am J Cardiol 91 (2003) 1123-1125
3. Boneu B., and Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 76 (1996) 939-943
4. Thebault J.J., Kieffer G., Lowe G.D., Nimmo W.S., and Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 25 (1999) 9-14
5. Aleil B., Ravanat C., Cazenave J.P., Rochoux G., Heitz A., and Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3 (2005) 85-92
6. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Cavallari U., Trabetti E., et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol 96 (2005) 1095-1099
7. Lepantalo A., Virtanen K.S., Heikkila J., Wartiovaara U., and Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 25 (2004) 476-483
8. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
9. Cuisset T., Frere C., Quilici J., Barbou F., Morange P.E., Hovasse T., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4 (2006) 542-549
10. Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the prepare post-stenting study. J Am Coll Cardiol 46 (2005) 1820-1826
11. Geisler T., Langer H., Wydymus M., Gohring K., Zurn C., Bigalke B., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27 (2006) 2420-2425
12. Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108 (2006) 2244-2247
13. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
14. von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., and Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112 (2005) 2946-2950
15. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
16. von Beckerath N., Kastrati A., Wieczorek A., Pogatsa-Murray G., Sibbing D., Graf I., et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J (2007) 10.1093/eurheartj/ehl489
17. Lenth R.V. Java applets for power and sample size [computer software] (2006). http://www.stat.uiowa.edu/~rlenth/Power [http://www.stat.uiowa.edu/~rlenth/Power]
18. Schulman S., and Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3 (2005) 692-694
19. Schwarz U.R., Geiger J., Walter U., and Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 82 (1999) 1145-1152
20. Geiger J., Teichmann L., Grossmann R., Aktas B., Steigerwald U., Walter U., et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 51 (2005) 957-965
21. Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59 (2003) 295-302
22. Bonello L., Paganelli F., Arpin-Bornet M., Auquier P., Sampol J., Dignat-George F., et al. VASP phosphorylation analysis prior to percutaneous coronary intervention for exclusion of post-procedural major adverse cardiovascular events. J Thromb Haemost (2007) 10.1111/j.1538-7836.2007.02609.x
23. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) 156-175
24. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Barrera Ramirez C., Sabate M., Fernandez C., et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 16 (2004) 169-174
25. Gilard M., Arnaud B., Le Gal G., Abgrall J.F., and Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 4 (2006) 2508-2509
26. Lau W.C., Waskell L.A., Watkins P.B., Neer C.J., Horowitz K., and Hopp A.S. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
27. Kotlyar M., and Carson S.W. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 37 (1999) 8-19
28. Kelly R.V., Hsu A., Topol E., and Steinhubl S. The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention. J Invasive Cardiol 18 (2006) 115-119
29. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 8 (2002) 1227-1234
30. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 96 (2005) 612-616